Stratos Wealth Partners LTD. Buys Shares of 3,969 Exact Sciences Co. (NASDAQ:EXAS)

Stratos Wealth Partners LTD. purchased a new position in Exact Sciences Co. (NASDAQ:EXAS) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,969 shares of the medical research company’s stock, valued at approximately $223,000.

A number of other institutional investors also recently made changes to their positions in the stock. Huntington National Bank increased its position in Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after purchasing an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in shares of Exact Sciences during the 3rd quarter worth about $34,000. Capital Performance Advisors LLP purchased a new stake in shares of Exact Sciences during the third quarter worth about $35,000. Vestor Capital LLC acquired a new position in shares of Exact Sciences in the third quarter valued at approximately $46,000. Finally, V Square Quantitative Management LLC purchased a new position in shares of Exact Sciences during the third quarter valued at approximately $47,000. 88.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on EXAS. Bank of America reduced their price target on Exact Sciences from $75.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Jefferies Financial Group increased their target price on Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. BTIG Research lifted their price target on Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Piper Sandler cut their price objective on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Finally, Craig Hallum lowered their target price on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, Exact Sciences has an average rating of “Moderate Buy” and a consensus target price of $72.76.

Exact Sciences Stock Performance

Shares of NASDAQ EXAS opened at $50.59 on Friday. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. The stock has a fifty day moving average price of $56.42 and a two-hundred day moving average price of $60.06. The firm has a market cap of $9.36 billion, a P/E ratio of -43.24 and a beta of 1.24.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.